Singapore-based firm to start human trials for Covid-19 treatment
Team Udayavani, Jun 12, 2020, 11:02 AM IST
Tychan, Singaporean biotechnology firm, will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19
The first phase of the trial will be conducted on healthy volunteers to determine the safety and tolerability of TY027, a monoclonal antibody or immune system protein that specifically targets the virus that causes Covid-19.
TY027 is being explored for its ability to slow down the progression of Covid-19 and speed up recovery, and its potential to provide temporary protection against infection
It is said that if phase one is successful, Tychan will seek approval for the antibody to be administered to a larger population of volunteer patients in subsequent trials.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
COP29: India rejects new USD 300 billion climate finance deal
Royal tour of India in offing for King Charles, Queen Camilla: Report
Indian-American leaders applaud PM Modi for inclusive growth in India
COP29: Civil society protests climate finance proposal, calls for ‘no deal’ over ‘bad deal’
Bomb disposal squad tackles ‘security incident’ at UK’s Gatwick Airport
MUST WATCH
Latest Additions
COP29: India rejects new USD 300 billion climate finance deal
Maharashtra Assembly Elections 2024 | Congress chief Nana Patole scrapes through in Sakoli, wins by 208 votes
Waqf land dispute: Kerala CM assures no body will be evicted from Munambam
Government launches Haj Suvidha App 2.0 for ease of pilgrims
VHP’s saint congregation resolves to fight against ‘Waqf Board land claims’
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.